Searchable abstracts of presentations at key conferences in endocrinology

ea0045p32 | Diabetes | BSPED2016

Emergency advice for families of children with diabetes – the story of a helpline

Grosser Sabine , Alexander Vicky

Objective: To describe the changes in out-of-hours emergency advice to families of children with diabetes over the last 15 years, the reasons for change and impact on hospital attendance.The local emergency clinical helpline for children with diabetes (DiabNet) was discontinued in August 2015. We have looked at its service and how it informed the support we deliver today, especially out of hours advice provided currently by paediatric registrars.<p c...

ea0093oc37 | Oral communication 5: Reproductive Endocrinology | EYES2023

Regulation of the postnatal activity of the HPG axis in male Callithrix jacchus – A project description

Odroniec Amadeusz , Busch Alexander

Background: The control of the Hypothalamic–Pituitary–Gonadal (HPG) axis is a highly complex process, with the hypothalamic arcuate-median eminence complex (Arc-ME) as the master regulating region. The transient activation of the HPG axis is essential for the development and function of the reproductive system. This project’s focus is the transient phase of HPG axis activation within the first weeks and months postpartum (minipuberty). The mechanisms guiding the...

ea0037ep790 | Pituitary: clinical | ECE2015

Prevalence of the sleep breathing disorders in untreated and treated patients with acromegaly

Ilovayskaya Irena , Dreval Alexander , Krivosheeva Yulia , Abramenko Alexander , Stashuk Galina

There are some data concerning high prevalence of infrasellar extension of somatotropinomas. To reveal any differences expansion of pitutary macroadenomas with various hormonal secretion, we have analyzed MRI data of 175 pituitary macroadenomas: 87 non-functioning adenomas (NFAs), 48 prolactinomas, 43 somatotropinomas. The sizes of pituitary tumour (vertical, sagittal, frontal): NFAs 24 (17.5; 34.5)mm, 23 (17.4; 28) mm, 23 (18; 30) mm; prolactinomas 21 (15; 31) mm, 20 (16; 30)...

ea0091wf11 | Workshop F: Disorders of the parathyroid glands, calcium metabolism and bone | SFEEU2023

A rare case of atypical parathyroid tumor with atypical presentation

Aye Thant Aye , Lewis Alexander

Introduction: Primary hyperparathyroidism is usually caused by a parathyroid adenoma (80-85%), occasionally by primary parathyroid hyperplasia (10-15%), and rarely by atypical parathyroid tumor (APT) or carcinoma (<1%). APT reflects parathyroid neoplasm of uncertain malignant potential which poses a challenge for differential diagnosis with parathyroid carcinomas. Most patients exhibit strong symptomatology of hypercalcemia at presentation shared with the benign causes of ...

ea0094p187 | Bone and Calcium | SFEBES2023

Hyperparathyroidism in the young: A case and investigation pathway

Aye Thant Aye , Lewis Alexander

Introduction: Primary hyperparathyroidism may be sporadic or occur as part of a genetic predisposition. Inactivation of CDC73 tumour suppressor gene can cause hyperparathyroidism-jaw tumour (HPT-IJ) syndrome, parathyroid carcinoma or familial isolated hyperparathyroidism (FIHP).Case details: We report a 26 year old gentleman, previously fit and well who was found to have hypercalcemia on a routine testing. Renal ultrasou...

ea0077p56 | Metabolism, Obesity and Diabetes | SFEBES2021

Novel regulation of GR mediated gene expression by PARP-1 in mouse skeletal muscle cells

Tan Arnold , Evans Alexander , Doig Craig

The glucocorticoid receptor is constitutively expressed and fundamental to life. Activity of GR is partially governed by interacting partners whose actions skew the frequency with which GR produces meaningful transcriptional outcomes. Moreover, the tissue-specific actions of GR are themselves defined, with binding patterns being distinct in various tissue types. These features mean full molecular understanding of this steroid hormone receptor remains incomplete. As glucocortic...

ea0081ep173 | Calcium and Bone | ECE2022

Palovarotene for the treatment of fibrodysplasia ossificans progressiva: methodology of the phase III open-label PIVOINE rollover trial

Artyomenko Alexander , Houchard Aude , Zemam Azzeddine

Objectives: Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder characterized by heterotopic ossification (HO) and progressive restriction of mobility. To date, no approved disease-modifying treatments for FOP exist, but interim phase III trial (NCT03312634) results suggest marked efficacy for palovarotene (PVO).1 Here, we describe methodology of the PIVOINE trial (NCT05027802) designed to allow treatment continuity and further evaluation o...

ea0069p22 | Poster Presentations | SFENCC2020

A Grave cause of hypercalcaemia in hypoparathyroidism

Abdel-Malek Mariana , Comninos Alexander , Cox Jeremy

Section 1: Case history: A 58 year old lady presented to the Emergency Department with a two week history of general lethargy, weight loss, increased thirst and polyuria as well as muscle cramps in her legs. Aside from sinus tachycardia, her observations and physical examination were unremarkable on admission. She had a background of hypertension on Indapamide as well as idiopathic hypoparathyroidism on Alfacalcidol. The latter had been diagnosed nine years prior following adm...

ea0062p66 | Poster Presentations | EU2019

Treatment of low bone density with a thiazide-like diuretic in idiopathic hypercalciuria

Almazrouei Raya , Comninos Alexander , Cox Jeremy

Case History: A 64 year old lady was referred for parental antiresorptive therapy due to a history of oral bisphosphonate intolerance. She had been screened for osteoporosis at age 53 after her mother had suffered a hip fracture, DEXA scan showed an L2-L4 T score of −2.5 and a mean femur −2.2. She was given a trial of alendronate, but had stopped due to indigestion. The DEXA scan at 4 years showed improvement of both the spine and femur densities on Calcium and Vit...

ea0063p62 | Calcium and Bone 1 | ECE2019

The effectiveness of colecalciferol and selective vitamin D receptor agonists treatment on secondary hyperparathyroidism in chronic kidney diseases patients

Egshatyan Lilit , Mokrisheva Natalia , Lutsenko Alexander

Background: Secondary hyperparathyroidism (SHPT) is an early complication of chronic kidney disease (CKD). Maintaining the level of 25(OH)D and parathyroid hormone concentrations in the target range reduce its associated complications (fractures and cardiovascular calcification).Aims: To examine the effectiveness of vitamin D supplementation and selective vitamin D receptor agonists treatment on SHPT in CKD.Materials and methods: P...